2Institute of Cyber Intelligence Systems, National Research Nuclear University MEPHI, 115409 Moscow, Russia
3Institute of Gene Biology of the Russian Academy of Sciences, 119334 Moscow, Russia
* To whom correspondence should be addressed.
Received: June 16, 2025; Revised: September 15, 2026; Accepted: September 22, 2026
The chemotherapeutic drug doxorubicin damages DNA of tumor cells, stopping their division. Some cells enter a metabolically active state of the therapy-induced senescence. These cells exhibit an increased dependence on glycolysis compared to untreated tumor cells, making glycolysis inhibitors potentially effective as part of combination therapy. We investigated effect of the glycolysis inhibitor 2-deoxy-D-glucose (2-DG) on the ability of the A375, A549, and MDA-MB-231 tumor cells to overcome the senescence stage induced by a low dose of doxorubicin and resume proliferation. 2-DG inhibited accumulation of reactive oxygen species (ROS) and ATP in the senescent cells, reduced expression of mRNA of the genes encoding the glucose transporter GLUT1 and the antioxidant enzyme SOD2 and limited exit of the cells from this state but did not affect apoptosis. A reversal experiment, conducted to assess relationship between the low ATP levels in the senescent cells and their limited ability to resume proliferation, showed that addition of pyruvate together with 2-DG predictably increased the ATP production and, at the same time, number of the cells that returned to division. Our results indicate that the mechanism of action of 2-DG involves depleting ATP in the cells undergoing senescence induced by low doses of doxorubicin, preventing their exit from this stage and return to division. 2-DG could be considered as a potential chemosensitizing agent that enhances efficacy of the standard chemotherapy.
KEY WORDS: 2-DG, apoptosis, chemoresistance, chemotherapy, doxorubicin, ROS, therapy-induced senescence, tumor cellsDOI: 10.1134/S0006297926602005
Publisher’s Note. Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.